29 April 2020

• NIAID issues a press release with preliminary results from the Adaptive COVID-19 Treatment Trial (ACCTT) of twice-daily infusions of remdesivir in hospitalized patients. It reported that remdesivir shortened the time to hospital release by 31% from a median of 15 days to 11 days. There was a numerical – but not statistically significant – difference in survival, with a death rate of 8% among people treated with remdesivir vs. 11.6% among people who got placebo. Source
• US President Trump asks the FDA to move as quickly as they can to approve remdesivir, saying ““We would like to see very quick approvals, especially with things that work.” Source

Return to the timeline